Financings Of The Fortnight: Rusnano Dodging Controversy, Transforming Into Private Equity Fund
This article was originally published in The Pink Sheet Daily
Executive Summary
The Russian sovereign fund is a major investor in several U.S. life sciences start-ups. Plus news on recent financings by SAGE Therapeutics, Macrogenics, G1 Therapeutics and TD1 Innovations.